Yulia Zharankova

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome”.

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Blood(2022)10.1182/blood.2022018546

N/A

3.2DataRank · unranked

132 citations

Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina +17 more

Interim analysis: Open-label extension study of leniolisib for patients with APDS

Journal of Allergy and Clinical Immunology(2023)10.1016/j.jaci.2023.09.032

N/A

1.2DataRank · unranked

40 citations

Elaine Kulm, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina +15 more

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis

Clinical Immunology(2024)10.1016/j.clim.2024.110400

N/A

0DataRank · unranked

16 citations

Anna Šedivá, Virgil A. S. H. Dalm, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina +14 more